Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of
modernized traditional Chinese medicine (“TCM”) based in
announced that it has received approvals from the Chinese State Food and Drug
Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in
dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial
and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA
approval number Z20090855).
Pediatric Fever and Cough Oral Liquid is a generic prescription TCM that
is used for respiratory tract infections and influenza of children to
effectively reduce symptoms such as fever, shakes, cough, phlem, shortness of
breath, dry mouth and sore throat. According to Tianyin’s market research and
estimation, annual sales of this type of products are approximately
billion
during the wintertime flu season and that our introduction of this product
will increase the Company’s market share in the pediatric medicine market.
Antibacterial and Anti-inflammatory Capsules is a generic OTC TCM which is
used mainly as natural antibiotics to treat bacterial infection and
inflammation. It has minimal side effects when compared to western
antibiotics. Tianyin estimates that total annual sales of antibacterial and
anti-inflammatory products are approximately
expects to gain a portion of the market share in antibiotics medicine through
the production and marketing of Antibacterial and Anti-inflammatory Capsules.
The product will be manufactured in Company’s new production facility.
“We are very pleased to receive approvals for our Pediatric Fever and
Cough Oral Liquid and Antibacterial and Anti-inflammatory Capsules from the
Chinese SFDA. One of our key growth strategies is to further expand our
portfolio,” Dr.
Inc., commented. “These products further complement our product portfolio and
create additional revenue opportunities for indications which we have not
previously addressed. We will immediately leverage current distribution
network and available production capacity to produce these two products.”
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine (“TCM”) in
current management team in
portfolio of 39 products, 22 of which are listed in the highly selective
National Medicine Catalog of the National Medical Insurance program. Tianyin
owns and operates two GMP manufacturing facilities and an R&D platform
supported by leading Chinese academic institutions. The Company has a
pipeline of 17 pharmaceutical products pending approval. Tianyin has an
extensive nationwide distribution network throughout
of 720 salespeople. Tianyin is headquartered in
with two manufacturing facilities and a total of 1,365 employees. For more
information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company’s filings with the
Securities and Exchange Commission.
For more information, please contact:
For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
Tel: +86-158-2122-5642
Email: Allen.y.tang@gmail.com
Investors:
Mr. Matthew Hayden, HC International
Tel: +1-561-245-5155
Email: matt.hayden@hcinternational.net
Web: http://www.hcinternational.net
SOURCE Tianyin Pharmaceutical Co., Inc.